Logo image of BMA

BANCO MACRO SA-ADR (BMA) Stock Fundamental Analysis

USA - NYSE:BMA - US05961W1053 - ADR

84.37 USD
-0.65 (-0.76%)
Last: 11/11/2025, 8:04:00 PM
84.37 USD
0 (0%)
After Hours: 11/11/2025, 8:04:00 PM
Fundamental Rating

3

Overall BMA gets a fundamental rating of 3 out of 10. We evaluated BMA against 388 industry peers in the Banks industry. BMA may be in some trouble as it scores bad on both profitability and health. BMA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

Each year in the past 5 years BMA has been profitable.
The reported operating cash flow has been mixed in the past 5 years: BMA reported negative operating cash flow in multiple years.
BMA Yearly Net Income VS EBIT VS OCF VS FCFBMA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500B -500B -1T -1.5T

1.2 Ratios

The Return On Assets of BMA (2.24%) is better than 97.42% of its industry peers.
With a Return On Equity value of 9.17%, BMA perfoms like the industry average, outperforming 55.93% of the companies in the same industry.
Industry RankSector Rank
ROA 2.24%
ROE 9.17%
ROIC N/A
ROA(3y)4.26%
ROA(5y)3.73%
ROE(3y)14.74%
ROE(5y)14.41%
ROIC(3y)N/A
ROIC(5y)N/A
BMA Yearly ROA, ROE, ROICBMA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

The Profit Margin of BMA (10.31%) is worse than 82.99% of its industry peers.
In the last couple of years the Profit Margin of BMA has declined.
The Operating Margin and Gross Margin are not available for BMA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 10.31%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-22.24%
PM growth 5Y-22.5%
GM growth 3YN/A
GM growth 5YN/A
BMA Yearly Profit, Operating, Gross MarginsBMA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20 25

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, BMA has about the same amount of shares outstanding.
Compared to 5 years ago, BMA has less shares outstanding
The debt/assets ratio for BMA has been reduced compared to a year ago.
BMA Yearly Shares OutstandingBMA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
BMA Yearly Total Debt VS Total AssetsBMA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5T 10T

2.2 Solvency

BMA has a Debt/Equity ratio of 0.23. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of BMA (0.23) is worse than 61.34% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACCN/A
BMA Yearly LT Debt VS Equity VS FCFBMA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2T 4T

2.3 Liquidity

Industry RankSector Rank
Current Ratio N/A
Quick Ratio N/A
BMA Yearly Current Assets VS Current LiabilitesBMA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200B 400B 600B 800B 1T

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BMA have decreased strongly by -18.65% in the last year.
The Earnings Per Share has been growing by 45.01% on average over the past years. This is a very strong growth
Looking at the last year, BMA shows a very negative growth in Revenue. The Revenue has decreased by -42.31% in the last year.
BMA shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 110.09% yearly.
EPS 1Y (TTM)-18.65%
EPS 3Y115.12%
EPS 5Y45.01%
EPS Q2Q%163.81%
Revenue 1Y (TTM)-42.31%
Revenue growth 3Y130.21%
Revenue growth 5Y110.09%
Sales Q2Q%-74.62%

3.2 Future

The Earnings Per Share is expected to grow by 58.17% on average over the next years. This is a very strong growth
BMA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 8.99% yearly.
EPS Next Y56.38%
EPS Next 2Y69.43%
EPS Next 3Y58.17%
EPS Next 5YN/A
Revenue Next Year-10.01%
Revenue Next 2Y-3.72%
Revenue Next 3Y8.99%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
BMA Yearly Revenue VS EstimatesBMA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 1T 2T 3T 4T 5T
BMA Yearly EPS VS EstimatesBMA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5K 10K 15K

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

Industry RankSector Rank
PE N/A
Fwd PE N/A
BMA Price Earnings VS Forward Price EarningsBMA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BMA Per share dataBMA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share

4.3 Compensation for Growth

A more expensive valuation may be justified as BMA's earnings are expected to grow with 58.17% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y69.43%
EPS Next 3Y58.17%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for BMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BANCO MACRO SA-ADR

NYSE:BMA (11/11/2025, 8:04:00 PM)

After market: 84.37 0 (0%)

84.37

-0.65 (-0.76%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupBanks
GICS IndustryBanks
Earnings (Last)08-28 2025-08-28/amc
Earnings (Next)11-25 2025-11-25
Inst Owners35.32%
Inst Owner Change2.49%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.30B
Revenue(TTM)4.02T
Net Income(TTM)414.02B
Analysts83.33
Price TargetN/A
Short Float %5.66%
Short Ratio1.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP59.04%
Div Incr Years2
Div Non Decr Years2
Ex-Date10-20 2025-10-20 (0.305083)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-3.47%
Min EPS beat(2)-24.13%
Max EPS beat(2)17.19%
EPS beat(4)1
Avg EPS beat(4)-24.51%
Min EPS beat(4)-51.11%
Max EPS beat(4)17.19%
EPS beat(8)3
Avg EPS beat(8)244.53%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-23.52%
Min Revenue beat(2)-23.64%
Max Revenue beat(2)-23.41%
Revenue beat(4)1
Avg Revenue beat(4)-19.43%
Min Revenue beat(4)-31.06%
Max Revenue beat(4)0.4%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-44.5%
EPS NY rev (1m)-1.2%
EPS NY rev (3m)-40.24%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.29%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)N/A
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpSN/A
BVpSN/A
TBVpSN/A
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 2.24%
ROE 9.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 10.31%
GM N/A
FCFM N/A
ROA(3y)4.26%
ROA(5y)3.73%
ROE(3y)14.74%
ROE(5y)14.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y-22.24%
PM growth 5Y-22.5%
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0.22
Health
Industry RankSector Rank
Debt/Equity 0.23
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 3.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio N/A
Quick Ratio N/A
Altman-Z N/A
F-Score1
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.07%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-18.65%
EPS 3Y115.12%
EPS 5Y45.01%
EPS Q2Q%163.81%
EPS Next Y56.38%
EPS Next 2Y69.43%
EPS Next 3Y58.17%
EPS Next 5YN/A
Revenue 1Y (TTM)-42.31%
Revenue growth 3Y130.21%
Revenue growth 5Y110.09%
Sales Q2Q%-74.62%
Revenue Next Year-10.01%
Revenue Next 2Y-3.72%
Revenue Next 3Y8.99%
Revenue Next 5YN/A
EBIT growth 1YN/A
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-144.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-112.41%
OCF growth 3YN/A
OCF growth 5YN/A

BANCO MACRO SA-ADR / BMA FAQ

What is the ChartMill fundamental rating of BANCO MACRO SA-ADR (BMA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to BMA.


Can you provide the valuation status for BANCO MACRO SA-ADR?

ChartMill assigns a valuation rating of 1 / 10 to BANCO MACRO SA-ADR (BMA). This can be considered as Overvalued.


Can you provide the profitability details for BANCO MACRO SA-ADR?

BANCO MACRO SA-ADR (BMA) has a profitability rating of 2 / 10.


What is the earnings growth outlook for BANCO MACRO SA-ADR?

The Earnings per Share (EPS) of BANCO MACRO SA-ADR (BMA) is expected to grow by 56.38% in the next year.